Folate Administration Regime Based on Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments involving folic acid and its derivatives, such as leucovorin, are not predictable and often result in unnecessary administration of non-active substances, leading to variable efficacy and toxicity, as not all patients can metabolize these compounds effectively into the active form [6R]-methylenetetrahydrofolate.
Innovation Solution
A method to determine folate substance administration regimes by quantifying the expression levels of specific genes (SLC46A1, SLC19A1, FPGS, ABCC3, MTHFD1L, GGH, MTHFD1, MTFMT, and ATIC) in patient samples, using real-time quantitative PCR, to tailor treatment with [6R]-methylenetetrahydrofolate or its upstream metabolites based on gene expression levels, thereby optimizing treatment outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If folic acid and its derivatives (e.g., leucovorin) are administered to all cancer patients, then the treatment can be universally applied, but the efficacy varies significantly and many patients receive non-active substances without benefit
Solution Approach 1:
The treatment approach is customized based on individual patient characteristics (gene expression profiles). Patients are stratified into different groups (Group 1 with high SLC46A1/SLC19A1 expression receiving leucovorin, Group 2 with low expression receiving [6R]-MTHF) based on their specific metabolic capabilities, rather than applying a uniform treatment to all patients
Solution Approach 2:
The invention changes the treatment parameter (type of folate substance administered) based on the measured gene expression levels. The decision to administer leucovorin versus [6R]-MTHF is determined by quantitative gene expression thresholds, transforming a static universal protocol into a dynamic personalized regimen
2Ease of manufacture
If folic acid and derivatives are administered to all patients, then the treatment protocol is simple and cost-effective, but unnecessary substances are administered to patients who cannot metabolize them effectively
Solution Approach 1:
Gene expression analysis is performed before treatment initiation to predict which patients will respond to leucovorin versus [6R]-MTHF. This preliminary characterization allows the treatment protocol to be optimized in advance for each patient, avoiding the waste of administering ineffective substances
Solution Approach 2:
The invention extracts and measures specific gene expression markers (SLC46A1, SLC19A1) from patient samples to identify the subset of patients who will benefit from leucovorin treatment. This extraction of predictive information allows for precise patient selection and avoidance of unnecessary treatment in non-responders
3Productivity
If leucovorin is administered to patients with low SLC46A1/SLC19A1 expression, then the treatment can be universally applied, but the anti-tumoral effect is not achieved in these patients
Solution Approach 1:
The treatment is tailored to match the specific metabolic capacity of each patient group. Group 1 patients (high transporter expression) receive leucovorin which they can activate, while Group 2 patients (low transporter expression) receive pre-activated [6R]-MTHF that does not require further metabolism, ensuring each group receives the form most suitable for their physiology
Solution Approach 2:
Instead of giving leucovorin to all patients and hoping for activation, the invention inverts the approach by giving the already-activated form ([6R]-MTHF) directly to patients who cannot perform the activation step, bypassing the metabolic bottleneck entirely
4Reliability
If gene expression analysis is performed to personalize treatment, then treatment efficacy and predictability improve, but the complexity of the treatment protocol increases
Solution Approach 1:
The complex biochemical process of folate metabolism and activation is replaced by a simple diagnostic measurement (gene expression analysis) followed by a straightforward treatment selection. Instead of monitoring multiple metabolic parameters or response indicators during treatment, a single baseline gene expression test determines the entire treatment course
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for personalized cancer treatment by identifying patients who benefit from [6R]-methylenetetrahydrofolate administration directly, enhancing treatment efficiency and predictability, reducing toxicity, and improving cost-effectiveness.
Implementation Method 1
The step of quantifying the expression level of at least one of said genes is performed by real-time quantitative PCR
Data Source
Figure 1
AI summary
A method for determining a folate substance administration regime is disclosed. The method comprises: quantifying, in a sample drawn from a patient, the expression level of at least one of the genes SLC46A1, SLC19A1, FPGS, ABCC3, MTHFD1L, GGH, MTHFD1, MTFMT, and ATIC; and establishing whether the expression level is high or low. A high expression level of at least one of said genes determines that said folate substance administration regime involves the administration of [6R]-methylenetetrahydrofolate and/or a folate substance upstreams of [6R]-methylenetetrahydrofolate in the metabolic pathway. A low expression level of at least one of said genes determines that said folate substance administration regime involves the administration of [6R]-methylenetetrahydrofolate. Also disclosed is a kit for determining such a folate substance administration regime.